Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Original Article

Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma

Chun-Ting Ho, Elise Chia-Hui Tan, Pei-Chang Lee, Chi-Jen Chu, Yi-Hsiang Huang, Teh-Ia Huo, Yu-Hui Su, Ming-Chih Hou, Jaw-Ching Wu, Chien-Wei Su

Clin Mol Hepatol. 2024;30(3):406-420. Published online April 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0103

View: 1341 Download: 109

Review

Liver sinusoidal endothelial cell: An important yet often overlooked player in the liver fibrosis

Jiaorong Qu, Le Wang, Yufei Li, Xiaojiaoyang Li

Clin Mol Hepatol. 2024;30(3):303-325. Published online February 28, 2024

DOI: https://doi.org/10.3350/cmh.2024.0022

View: 1634 Download: 186

Snapshot

Immunopathogenesis of liver fibrosis in steatotic liver disease

Chaerin Woo, Won-Il Jeong

Clin Mol Hepatol. 2024;30(2):299-302. Published online February 19, 2024

DOI: https://doi.org/10.3350/cmh.2024.0113

View: 2121 Download: 85

Review

Identification of high-risk subjects in nonalcoholic fatty liver disease

Christiane Stern, Laurent Castera

Clin Mol Hepatol. 2023;29(Suppl):S196-S206. Published online December 5, 2022

DOI: https://doi.org/10.3350/cmh.2022.0431

View: 5813 Download: 280 Web of Science: 8 Crossref: 10

Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future

Tina Reinson, Ryan M. Buchanan, Christopher D. Byrne

Clin Mol Hepatol. 2023;29(Suppl):S157-S170. Published online November 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0348

View: 4285 Download: 308 Web of Science: 17 Crossref: 17

Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future

Jung Hwan Yu, Han Ah Lee, Seung Up Kim

Clin Mol Hepatol. 2023;29(Suppl):S136-S149. Published online December 12, 2022

DOI: https://doi.org/10.3350/cmh.2022.0436

View: 4219 Download: 222 Web of Science: 17 Crossref: 17

Screening strategy for non-alcoholic fatty liver disease

Saisai Zhang, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto

Clin Mol Hepatol. 2023;29(Suppl):S103-S122. Published online November 30, 2022

DOI: https://doi.org/10.3350/cmh.2022.0336

View: 5035 Download: 231 Web of Science: 13 Crossref: 15

Non-alcoholic fatty liver disease: Definition and subtypes

Seul Ki Han, Soon Koo Baik, Moon Young Kim

Clin Mol Hepatol. 2023;29(suppl):S5-S16. Published online December 28, 2022

DOI: https://doi.org/10.3350/cmh.2022.0424

View: 7075 Download: 502 Web of Science: 35 Crossref: 36

Correspondence

Correspondence on Letter regarding “Non-alcoholic fatty liver disease: Definition and subtypes”

Seul Ki Han, Soon Koo Baik, Moon Young Kim

Clin Mol Hepatol. 2023;29(3):817-819. Published online May 17, 2023

DOI: https://doi.org/10.3350/cmh.2023.0155

View: 2012 Download: 47

Original Article

Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis

Yu Jun Wong, Vy H. Nguyen, Hwai-I Yang, Jie Li, Michael Huan Le, Wan-Jung Wu, Nicole Xinrong Han, Khi Yung Fong, Elizebeth Chen, Connie Wong, Fajuan Rui, Xiaoming Xu, Qi Xue, Xin Yu Hu, Wei Qiang Leow, George Boon-Bee Goh, Ramsey Cheung, Grace Wong, Vincent Wai-Sun Wong, Ming-Whei Yu, Mindie H. Nguyen

Clin Mol Hepatol. 2023;29(3):705-720. Published online May 8, 2023

DOI: https://doi.org/10.3350/cmh.2023.0004

View: 4323 Download: 233 Web of Science: 14 Crossref: 19

Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase

Jeong-Ju Yoo, Soo Young Park, Ji Eun Moon, Yu Rim Lee, Han Ah Lee, Jieun Lee, Young Seok Kim, Yeon Seok Seo, Sang Gyune Kim

Clin Mol Hepatol. 2023;29(2):482-495. Published online January 5, 2023

DOI: https://doi.org/10.3350/cmh.2022.0322

View: 3830 Download: 194 Web of Science: 12 Crossref: 15

Taurocholic acid promotes hepatic stellate cell activation via S1PR2/p38 MAPK/YAP signaling under cholestatic conditions

Jing Yang, Xujiao Tang, Zhu Liang, Mingzhu Chen, Lixin Sun

Clin Mol Hepatol. 2023;29(2):465-481. Published online February 20, 2023

DOI: https://doi.org/10.3350/cmh.2022.0327

View: 5312 Download: 248 Web of Science: 6 Crossref: 9

Editorial

Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future

Kee-Huat Chuah, Wah-Kheong Chan

Clin Mol Hepatol. 2023;29(2):401-403. Published online February 28, 2023

DOI: https://doi.org/10.3350/cmh.2023.0062

View: 2723 Download: 65 Web of Science: 1 Crossref: 2

Non-invasive biomarkers of liver fibrosis in non-alcoholic fatty liver disease

Maamon Basheer, Mohamed Naffaa, Nimer Assy

Clin Mol Hepatol. 2023;29(2):398-400. Published online February 13, 2023

DOI: https://doi.org/10.3350/cmh.2023.0045

View: 3106 Download: 133

Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future

Lynna Alnimer, Mazen Noureddin

Clin Mol Hepatol. 2023;29(2):394-397. Published online April 1, 2023

DOI: https://doi.org/10.3350/cmh.2023.0104

View: 2751 Download: 87 Web of Science: 1

Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?

Joo Hyun Oh, Dong Hyun Sinn

Clin Mol Hepatol. 2023;29(2):367-370. Published online March 20, 2023

DOI: https://doi.org/10.3350/cmh.2023.0054 Correction in: Clin Mol Hepatol 2023;29(3):828

View: 2627 Download: 66 Web of Science: 3 Crossref: 2

Review

Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Kuei-Chuan Lee, Pei-Shan Wu, Han-Chieh Lin

Clin Mol Hepatol. 2023;29(1):77-98. Published online October 13, 2022

DOI: https://doi.org/10.3350/cmh.2022.0237

View: 9944 Download: 655 Web of Science: 40 Crossref: 47

Original Article

Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF- κB signaling pathways

Seung Min Lee, Dong Hee Koh, Dae Won Jun, Yoon Jin Roh, Hyeon Tae Kang, Ju Hee Oh, Hyun Sung Kim

Clin Mol Hepatol. 2022;28(4):827-840. Published online June 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0068

View: 7128 Download: 380 Web of Science: 17 Crossref: 18

Editorial

Repurposing drugs to target nonalcoholic steatohepatitis: Auranofin, a gold-organic molecule complex for the treatment of a specifc complex trait

Carlos J. Pirola, Silvia Sookoian

Clin Mol Hepatol. 2022;28(4):806-809. Published online August 19, 2022

DOI: https://doi.org/10.3350/cmh.2022.0208

View: 2572 Download: 68

Letter to the Editor

Effects of interleukin-17 inhibitors on hepatic fibrosis index in patients with psoriasis and metabolic dysfunction-associated fatty liver disease: Directed acyclic graphs

Saori Takamura, Yuichi Teraki, Eri Katayama, Takumi Kawaguchi, Machiko Kawaguchi, Dan Nakano, Tsubasa Tsutsumi, Sumiko Nagoshi, Takekuni Nakama, Takuji Torimura

Clin Mol Hepatol. 2022;28(2):269-272. Published online February 15, 2022

DOI: https://doi.org/10.3350/cmh.2022.0040

View: 5152 Download: 338 Web of Science: 7 Crossref: 8

Original Article

U-shaped relationship between urea level and hepatic decompensation in chronic liver diseases

Huapeng Lin, Grace Lai-Hung Wong, Xinrong Zhang, Terry Cheuk-Fung Yip, Ken Liu, Yee Kit Tse, Vicki Wing-Ki Hui, Jimmy Che-To Lai, Henry Lik-Yuen Chan, Vincent Wai-Sun Wong

Clin Mol Hepatol. 2022;28(1):77-90. Published online November 5, 2021

DOI: https://doi.org/10.3350/cmh.2021.0188

View: 5960 Download: 146 Web of Science: 16 Crossref: 15

Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B

Lilian Yan Liang, Hye Won Lee, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip, Yee-Kit Tse, Vicki Wing-Ki Hui, Grace Chung-Yan Lui, Henry Lik-Yuen Chan, Grace Lai-Hung Wong

Clin Mol Hepatol. 2021;27(3):499-509. Published online February 26, 2021

DOI: https://doi.org/10.3350/cmh.2020.0333

View: 4952 Download: 137 Web of Science: 14 Crossref: 14

Review

Anti-fibrotic treatments for chronic liver diseases: The present and the future

Naoshi Odagiri, Tsutomu Matsubara, Misako Sato-Matsubara, Hideki Fujii, Masaru Enomoto, Norifumi Kawada

Clin Mol Hepatol. 2021;27(3):413-424. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0187

View: 14227 Download: 476 Web of Science: 25 Crossref: 26

Original Article

Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B

Mi Young Jeon, Beom Kyung Kim, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim

Clin Mol Hepatol. 2021;27(2):295-304. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0216

View: 5596 Download: 211 Web of Science: 17 Crossref: 21

Editorial

Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact

Terry Cheuk-Fung Yip, Grace Lai-Hung Wong, Vincent Wai-Sun Wong

Clin Mol Hepatol. 2021;27(2):273-277. Published online February 1, 2021

DOI: https://doi.org/10.3350/cmh.2021.0019

View: 4583 Download: 136 Web of Science: 5 Crossref: 6

Marta Tonon, Salvatore Piano

Clin Mol Hepatol. 2021;27(1):94-96. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0305

View: 4488 Download: 143 Web of Science: 7 Crossref: 7

Review

Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective

Gwyneth Soon, Aileen Wee

Clin Mol Hepatol. 2021;27(1):44-57. Published online November 19, 2020

DOI: https://doi.org/10.3350/cmh.2020.0181

View: 12800 Download: 361 Web of Science: 35 Crossref: 37

Special topic: Alcoholic liver diseases The 14th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPDC)

Emerging medical therapies for severe alcoholic hepatitis

David Tornai, Gyongyi Szabo

Clin Mol Hepatol. 2020;26(4):686-696. Published online September 28, 2020

DOI: https://doi.org/10.3350/cmh.2020.0145

View: 6303 Download: 222 Web of Science: 16 Crossref: 16

Review

Role of cytoglobin, a novel radical scavenger, in stellate cell activation and hepatic fibrosis

Le Thi Thanh Thuy, Hoang Hai, Norifumi Kawada

Clin Mol Hepatol. 2020;26(3):280-293. Published online June 4, 2020

DOI: https://doi.org/10.3350/cmh.2020.0037

View: 7767 Download: 235 Web of Science: 13 Crossref: 13

Original Article

Influence of some methylated hepatocarcinogenesis-related genes on the response to antiviral therapy and development of fibrosis in chronic hepatitis C patients

Waleed Seif Eldin Mohamed Mostafa, Mohammed Hassan Saiem Al-Dahr, Dalia Abdel Hamid Omran, Zeinab Fathy Abdullah, Suzan Hamdy Elmasry, Mohamed Nabil Ibrahim

Clin Mol Hepatol. 2020;26(1):60-69. Published online October 22, 2019

DOI: https://doi.org/10.3350/cmh.2019.0051

View: 6305 Download: 137 Web of Science: 4 Crossref: 4

1 | 2 | 3 |

Viewed By 5662	MAFLD: How is it different from NAFLD?
Viewed By 5579	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5386	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 5336	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4988	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 176	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 119	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 113	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 91	MAFLD: How is it different from NAFLD?
Cited By 82	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Search